---
title: 'Geriatric Assessment of Older Patients Receiving Trabectedin in First-Line
  Treatment for Advanced Soft Tissue Sarcomas: The E-TRAB Study from The German Interdisciplinary
  Sarcoma Group (GISG-13)'
date: '2024-02-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38339308/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240210170637&v=2.18.0
source: heidelberg[Affiliation]
description: E-TRAB was a non-interventional, prospective trial investigating the
  feasibility and predictive value of geriatric assessments (GA) in older STS patients
  treated with trabectedin as first-line therapy. Primary endpoints were overall survival
  (OS), quality of life and individual clinical benefit assessed by the patient-reported
  outcome measures QLQ-C30 and PRO-CTCAE. Further, several GA tools were applied and
  correlated with clinical outcomes and treatment-related toxicities. The final ...
disable_comments: true
---
E-TRAB was a non-interventional, prospective trial investigating the feasibility and predictive value of geriatric assessments (GA) in older STS patients treated with trabectedin as first-line therapy. Primary endpoints were overall survival (OS), quality of life and individual clinical benefit assessed by the patient-reported outcome measures QLQ-C30 and PRO-CTCAE. Further, several GA tools were applied and correlated with clinical outcomes and treatment-related toxicities. The final ...